LONDON — For Keir Starmer, the crises and climbdowns just keep getting faster. The British prime minister, facing questions about his judgment in appointing Peter Mandelson as U.K. ambassador to Washington despite his Jeffrey Epstein links, pledged on Wednesday to publish a cache of emails and texts between the ex-Labour peer and his top team — on his own terms. But hours later he was forced to toughen up independent scrutiny of this document release in the face of a revolt by his own MPs, who are horrified by the scandal and fear opposition accusations of a cover-up will stick. Taken alone, this technical U-turn will not enter any history books. But the last-minute drama around it puts the already weak Labour leader in further peril. Nervous MPs in his governing party, now awaiting the document dump with deep unease, are rounding with renewed ferocity on the PM and his chief of staff Morgan McSweeney. POLITICO spoke to 20 Labour MPs and current and former officials for this piece. “We need a head,” said one moderate Labour MP who entered parliament in 2024 and was, like others quoted, granted anonymity to speak frankly. “Someone has to pay the price for this failure,” a second, usually loyal, MP from the 2024 intake said, adding they “wouldn’t care” who exactly it was. In the minds of many of Labour’s own MPs and officials, the Mandelson affair has further weakened Starmer and McSweeney, who pushed for the appointment of his close ally and friend as ambassador in late 2024. After rows over a succession of tax and policy U-turns, some believe the Mandelson crisis exemplifies their criticisms of Starmer’s leadership — paying too little attention to a potential problem until it blows up into a full-blown scandal. “I love Morgan, but Keir has to sack him and he should have sacked him a long time ago,” said one Labour official who has long been loyal to the leadership. “The problem is, who does Keir replace him with?” TAINTED BY MANDELSON Starmer defended McSweeney to the hilt on Wednesday. “Morgan McSweeney is an essential part of my team,” he told MPs. “He helped me change the Labour Party and win an election. Of course I have confidence in him,” the PM said. Some MPs also rallied around Starmer, blaming an overexcited media narrative and MPs on edge for the next scandal. “This feels like a Westminster story at the moment rather than something terminal for the PM in the eyes of the public,” said a third Labour MP elected in 2024. But the mood in large parts of the party on Wednesday night was bleak. The latest round of bloodletting began in earnest on Monday, when emails released as part of the Epstein files appeared to show Mandelson leaking government financial discussions in the wake of the 2008 banking crash. Police are now investigating allegations of misconduct in public office. Mandelson didn’t immediately respond to a request for comment on the police investigation Tuesday evening. He has previously said he was wrong to have continued his association with Epstein and apologized “unequivocally” to Epstein’s victims. Starmer, like the rest of the British state and public, insists he did not know about the bombshell emails, and would never have appointed Mandelson if he did. Having already sacked Mandelson in September he is now obliterating his reputation, saying on Wednesday that Mandelson “lied repeatedly” during his appointment as ambassador.  Yet it was well known that Mandelson came with baggage. Starmer knew the former Labour Cabinet minister had been repeatedly sacked in scandal — and confirmed at the weekly Prime Minister’s Questions session on Wednesday that he had known Mandelson was friends with Epstein. “That was the moment,” said a fourth, moderate Labour MP. “The mood was awful. I had opposition MPs saying to me that they had not seen one that bad in decades.” Several Labour MPs and officials who spoke to POLITICO voiced fears that revealing details of the vetting process will paint Starmer and his chief of staff as too incurious about the wider situation. Mandelson had worked closely with McSweeney since the late 2010s and gave Labour informal advice in the run-up to its 2024 election landslide. One former No. 10 official said Mandelson was not on the list of potential ambassadors until McSweeney took over as chief of staff in October 2024, claiming: “Morgan didn’t do anything without speaking to Peter.” “Once the timeline — and the degree to which searching questions were asked — become clear, I think Morgan might be in trouble,” one U.K. government official added. Mandelson went through at least three layers of checks, a second U.K. government official said. Before his role was announced, the Cabinet Office carried out due diligence. Afterward, he was subjected to full deep security vetting. The third layer — and potentially the most problematic for Starmer and McSweeney — was a letter to Mandelson before his appointment from the chief of staff on the PM’s behalf. It asked three questions: why he continued contact with Epstein after his conviction, why he was reported to have stayed in one of Epstein’s home when the financier was in prison, and whether he was associated with a charity founded by Epstein’s associate Ghislaine Maxwell. A No. 10 official said reports that linked Mandelson to Epstein, including after he was first convicted, had been looked into as part of the appointment process. “Peter Mandelson lied to the Prime Minister, hid information that has since come to light and presented Epstein as someone he barely knew,” the No. 10 official added. HURRY UP AND WAIT Some Labour MPs — spooked by consistent polls putting Labour behind Nigel Farage’s populist Reform UK — are so angry that they want to see regime change immediately. For many on Labour’s left or “soft left” flank this was simply a chance to push their campaign against No. 10. One former minister, already hostile to the leadership, said it felt like the worst part of Starmer’s premiership and McSweeney should go now. Left-wing former Labour Leader Jeremy Corbyn, long cast out of the party over comments on antisemitism, went on Sky News to say Starmer may even be challenged before local elections, which will be held across the U.K. in May. Others were new converts to immediate action. A fifth Labour MP, a moderate who entered parliament in 2024, also said McSweeney should go now. They lamented the “blind spot for many in the leadership” who allowed Mandelson to become ambassador. It has left some MPs angry and dejected. One, Sarah Owen, made an impassioned intervention in Wednesday’s debate: “Don’t we need to put the victims at the heart of this, not just ourselves?” But they will have to wait if they want the facts behind the case to become clear. MPs agreed on Wednesday night to release a series of documents concerning the diligence and vetting around Mandelson’s appointment, as well as communications he had with McSweeney, ministers, civil servants and special advisers in the six months before his appointment. Starmer had intended to block the release of any documents that would prejudice U.K. national security or international relations. But No. 10 staged a late climbdown after Angela Rayner — a key figure among MPs on Labour’s “soft left” who resigned as deputy prime minister amid a housing scandal in September — called for parliament’s Intelligence and Security Committee (ISC) to have a role. Officials scrambled to compile a new amendment that would give the ISC the final say on what is blocked. It will likely take days or weeks for the government to work through what needs to be released, and far longer for the ISC to work through the most contentious documents after that. The Met Police also released a statement on Wednesday night warning the release of specific documents “could undermine” its current investigation into Mandelson’s alleged misconduct in public office. The releases — which could include Mandelson’s private messages to friends in the Cabinet, such as Health Secretary Wes Streeting — will provide easy fodder to a British media gripped by the stories of Epstein’s friendships with Mandelson and Andrew Mountbatten-Windsor, formerly known as Prince Andrew. But most MPs and officials who spoke to POLITICO agreed that No. 10 and McSweeney stand to lose the most. A second former No. 10 official said: “Lots of people are nice to creepy people in politics. But when it comes down to the brass tacks of who knew what or did what when they made the appointment — that’s the chopping block stuff.” A sixth Labour MP, on the left of the party, said even frontbenchers were “questioning why they should jeopardise their own positions to protect one individual [McSweeney].” But the question of “when” remains a key one.  One Labour figure loyal to Starmer’s No. 10 admitted there will be pressure for McSweeney to go now, but insisted anyone with an ounce of political sense would delay any move against him until after local elections in May — so that he could absorb the blame for any losses and protect the PM. Even a staunch ally of McSweeney — who has been at Starmer’s side since he first ran to be Labour leader — said they had no idea if he will survive. But a seventh Labour MP, elected in 2024, thinks questions over McSweeney’s future are a red herring. “It’s ultimately about the PM’s judgement,” they said. The fourth Labour MP quoted above added: “If one of them goes, the other one has to go too.” Esther Webber contributed reporting.

LONDON — Peter Mandelson spent four decades helping build Britain’s Labour establishment. Now it’s decisively cutting him adrift. Former colleagues in the Cabinet and Labour Party officialdom lined up to blowtorch Britain’s former ambassador to the U.S. on Tuesday after newly released files suggested he leaked sensitive government financial discussions to the convicted sex offender Jeffrey Epstein in 2009. “The latest revelations are materially different to the unpleasant sleaze of previous revelations,” David Blunkett, a former home secretary under Tony Blair, told POLITICO. “This is about conduct in a public office, betrayal of colleagues and a dereliction of duty.” Geoff Hoon, Blair’s former defense secretary, told GB News it was “very disturbing,” while Labour grandee Harriet Harman told BBC radio: “I was of the view that Peter Mandelson was untrustworthy from the 1990s.” Prime Minister Keir Starmer sacked the so-called “prince of darkness” as Britain’s envoy to Washington in September as the extent of his friendship with Epstein became clear. But to many former colleagues, Monday’s revelation that Mandelson allegedly disclosed internal emails went much further — and will trigger, they believe, the end of his time in public life.  Mandelson declined to comment for this piece. He has previously said he was wrong to have continued his association with Epstein and apologized “unequivocally” to Epstein’s victims. Starmer said on Saturday that he had “nothing more to say” on Mandelson. That didn’t last. Smelling public outrage, the PM told his Cabinet Tuesday that the fresh allegations were “disgraceful.” Mandelson, 72, quit his seat for life in the House of Lords on Tuesday after Starmer — having earlier declined to do so — said ministers would draft a law to remove him from the upper house. Police are reviewing whether the allegations could amount to misconduct in a public office. Ex-Prime Minister Gordon Brown — who brought Mandelson back into government in 2008 — issued a statement tearing into the “shocking” revelations, and revealing he asked civil servants to investigate Mandelson’s communications with Epstein in September. Brown also contacted police Tuesday. One former diplomat, granted anonymity to speak undiplomatically, called the flurry of statements a “public lynching.” They added: “He’s going now through Dante’s seven circles of hell, and every time it looks like he’s reached the bottom, another circle appears.” One of British politics’ greatest survivors, Mandelson has not arrived at the last circle yet. Prime Minister Keir Starmer sacked the so-called “prince of darkness” as Britain’s envoy to Washington in September as the extent of his friendship with Epstein became clear. | Tolga Akmen/EPA Several of his close personal allies kept their counsel when contacted on Tuesday. Former Prime Minister Tony Blair has not yet decided to comment. Another of Labour’s most senior figures told POLITICO that they had no publishable comment. But Luke Sullivan, who was a junior special adviser in the late 2000s, and later became Starmer’s political director in opposition, said: “I cannot tell you how angry people are.” Another former aide from the New Labour years, granted anonymity to speak frankly, added: “Bloody hell, it is worse than we thought. People feel justifiably sad and angry. This is not a story of people turning on him. It’s more like a Greek tragedy — Peter has been brought down by his fatal flaw, and it’s a flaw that people were always aware of.” AT THE HEART OF POWER Whenever Labour reached a turning point in its recent history, Mandelson was somehow there. Pairing a smooth-talking style with ruthless maneuvering behind the scenes, he began as the party’s communications director in 1985 and embarked on a mission with then-leader Neil Kinnock to drag his party back from the left. He became MP for Hartlepool in 1992, playing a key role in Blair’s 1994 election as party leader and Labour’s 1997 general election landslide. He was never far from scandal, resigning from the Cabinet first in 1998 over a loan he took from a colleague, then again in 2001 in a row over a passport application from an Indian billionaire. Yet his attraction to power and strategic skills made his return inevitable. In 2008, already back as Britain’s EU trade commissioner, he repaired ties with Brown, who had recently become prime minister, in an hour-long private meeting in Brussels, before returning to the heart of government. The next year, when Cabinet minister James Purnell resigned and called on Brown to stand aside, Mandelson is said to have come into No. 10 and persuaded the rebels to back down. Peter Mandelson began as the party’s communications director in 1985 and embarked on a mission with then-leader Neil Kinnock to drag his party back from the left. | Will Oliver/EPA Nigel Farage, leader of the populist right-wing party Reform UK, said on Tuesday: “He’s very articulate. He’s highly intelligent. He’s incredibly well-briefed, probably the best networker in Westminster in the last 30 years.” “[On] the actual subject, the brief … I’d never heard anybody as impressive in all my 20 years in the European Parliament. The guy is very, very bright, but clearly has a taste for money, and has a taste for bad company.” Labour went on to lose the 2010 election — though by a slimmer margin than many expected — and Mandelson co-founded a lobbying firm, Global Counsel. (The firm began cutting ties with him last year.) But in the late 2010s, he returned to politics, striking up a close professional relationship with Morgan McSweeney, now Starmer’s chief of staff. Along with other Labour aides, the pair attended dinners at the south London home of the Labour peer Roger Liddle to discuss how best to wrestle Labour back (again) from the left. His advice became more valued in the run-up to the 2024 election. He even co-presented a podcast, produced by The Times newspaper, called “How To Win An Election.” And late in 2024 — at the suggestion of McSweeney, despite concerns elsewhere in government — Mandelson bagged his biggest prize yet: the ambassadorship to Washington. Starmer jokingly compared Mandelson to Donald Trump in a February 2025 speech at the embassy: “You can sense that there’s a new leader. He’s a true one-off, a pioneer in business, in politics. Many people love him. Others love to hate him. But to us, he’s just … Peter.” TURNING ON MANDELSON In four decades, Mandelson made plenty of enemies who are now glad to see his demise. The difference with this scandal may be the reaction of those close to him. Nigel Farage, leader of the populist right-wing party Reform UK, said on Tuesday: “He’s very articulate. He’s highly intelligent. He’s incredibly well-briefed, probably the best networker in Westminster in the last 30 years.” | Andy Rain/EPA Wes Streeting, Starmer’s telegenic health secretary, who shares many aspects of Mandelson’s politics and is widely expected to be a future leadership contender, was at some of the Liddle dinners. He told the BBC: “This is a betrayal on so many levels. It is a betrayal of the victims of Jeffrey Epstein that he continued that association and that friendship for so long after his conviction. It is a betrayal of just not one, but two prime ministers.” Privately, Mandelson is said to believe he was simply casting around for advice during the worst financial crisis since the 1930s. He told the Times: “There was no reason to shun his advice, but I was too trusting.” He added: “Work has always defined me. Everything else has always been an add-on. So I will find things to do.” But one serving Labour official in government said the revelations were “qualitatively (and quantitatively) worse” than what was known before. A second Labour official added: “The latest revelations have put him beyond what most people are willing to accept.” One person who speaks to No. 10 regularly said: “There are people who have known him for a long time who are very hurt and angry. He has upset people.  “He had a much reduced reservoir of support coming into this anyway, and the question is — who is going to touch him now?” Ex-Prime Minister Gordon Brown — who brought Mandelson back into government in 2008 — issued a statement tearing into the “shocking” revelations. | Will Oliver/EPA A person who knows Mandelson well drew a distinction between the reaction to his sacking in September, when some colleagues felt concern for Mandelson on a “human level because of the very public nature of his sacking,” and the “shock and real anger” at the revelations of the last few days. “It felt like a kick in the gut to read it and has brought his behavior as minister into question in a way no one could possibly have imagined,” they said. Sullivan said: “People thought that he had been characteristically not as frank as he could be with his relationship with Epstein … but I don’t think people had clocked just quite how big the significance of those revelations [Monday] are. “Any one of those, if it had come out at the time, would have brought the government down. I was a very junior Spad in the last Labour government. [With] Gordon Brown, you could hear the anger in his statement.” “I think the potential ramifications of this not just for the Labour Party but for politics and politicians in general could be understated. It is serious,” Sullivan added. The former diplomat quoted above added: “People are genuinely astonished at the sort of stuff he told Epstein. He always had a reputation of being relatively indiscreet, but some of that stuff, I mean, why Epstein? I don’t know why Epstein seemed to have had such a grip on him.” John McTernan, who served as a senior aide during the New Labour years, said: “It turns out that Peter’s actions are those of an avaricious man — which makes it really sad, because he did so much to make Labour electable, not once but twice.” WHERE DOES IT GO FROM HERE? Britain’s opposition Conservative Party is likely to apply fresh pressure on Wednesday by formally demanding that ministers release the details of Mandelson’s vetting for the ambassador post. Foreign Secretary Yvette Cooper revealed in September that Mandelson was not subjected to full national security vetting until after his appointment had been announced.  One government official said: “If there wasn’t any real vetting until after the appointment, that could be very damaging in my view.” Labour officials also smell danger in the fact that Gordon Brown asked the government to investigate Mandelson’s communications on Sept. 10 — a day before Starmer resolved to sack Mandelson as ambassador. The Labour Party has said disciplinary action was underway against Mandelson before he resigned his party membership on Sunday, but has not said when it began — days, weeks, or months ago. One former Labour official said: “The problem for the government as a whole and the civil service is Gordon clearly clocked something had gone on, had some concerns, and raised them last September, and it’s unclear exactly what has happened to dig it out.” No. 10 went nuclear in its response on Tuesday, saying the government was investigating and had contacted the police. Starmer’s spokesperson said: “An initial review of the documents released in relation to Jeffrey Epstein by the U.S. Department of Justice has found that they contain likely market-sensitive information surrounding the 2008 financial crash and official activities thereafter to stabilize the economy.  “Only people operating in an official capacity had access to this information, [with] strict handling conditions to ensure it was not available to anyone who could potentially benefit from it financially. It appears these safeguards were compromised.  “In light of this information, the Cabinet Office has referred this material to the police.” Starmer and McSweeney can maintain that they — like the rest of the press and British public — knew nothing of the emails revealed this week when they appointed Mandelson. Whether they can prevent the saga raising questions about their judgment may be another matter.

LONDON — Britain’s leading opposition politician has joined calls for British royal Andrew Mountbatten-Windsor to testify in the United States over his links to Jeffrey Epstein. Nigel Farage, the right-wing populist whose party, Reform UK is leading opinion polls, said that giving evidence to a U.S. congressional investigation about Epstein could be the former prince’s only chance to clear his name. “If Andrew believes that, yep his judgment was flawed, yep he did things he shouldn’t have done, but they weren’t coercive, they weren’t outside the law, if he believes those things, then he ought to go … for his own sake, and testify,” Farage said. “If he doesn’t go, he’d probably never be able to show his face in public again,” the Reform leader added, warning it is “probably the only chance he’s got, to some degree … at least I think, to clear his name.” In 2019, Mountbatten-Windsor was accused in a civil lawsuit of sexually assaulting Virginia Giuffre, one of Epstein’s accusers, but he strongly denied all allegations. He paid a financial settlement to Giuffre, but accepted no liability. The royal has faced a backlash over his friendship with Epstein, but has not been charged with a crime in either the U.K. or the U.S. He missed a November deadline to sit for a transcribed interview that was set by the U.S. House of Representatives’ Committee on Oversight and Government Reform. Farage’s intervention comes after Keir Starmer suggested that Mountbatten-Windsor should appear before U.S. lawmakers. The British prime minister told reporters last week that anyone with information “should be prepared to share that information in whatever form they are asked to,” adding: “You can’t be victim-centered if you’re not prepared to do that.” Mountbatten-Windsor is under renewed pressure to testify after the latest tranche of Epstein files released by the U.S. Department of Justice included a picture which appears to show King Charles’ brother crouching on all fours over an unknown woman. An email exchange dated August 2010, also released Friday, showed Epstein offered the then-Duke of York the opportunity to have dinner with a woman he described as “26, russian, clevere beautiful, trustworthy.” Mountbatten-Windsor replied: “That was quick! How are you? Good to be free?” The exchange happened a year after Epstein was released from jail following a sentence for soliciting prostitution from a person under 18.

The UK has historically been a global leader in life sciences innovation, but recent statistics paint a worrying picture for medicines access. The right policy can start to reverse this. We are living in a time where the intersection between breakthrough science, technology and data insights has the potential to transform treatment options for some of the toughest health conditions faced by patients in the UK. The UK has long played a central role in driving innovation when it comes to healthcare, and at Johnson & Johnson (J&J) we were pleased to see some positive signs from the Government at the end of 2025, illustrating an intent to reverse a decade of decline of investment in how the UK values innovative treatments. It was a positive first step, but now the real work begins to enable us to deliver the best possible outcomes for UK patients. To achieve this, our focus must be on ensuring our health system is set up to match the pace and gain the benefits of innovation that science provides. We need a supportive medicines environment that fully fosters growth, because even the most pioneering drugs and therapies are only valuable if they can be accessed by patients when they need them most. > even the most pioneering drugs and therapies are only valuable if they can be > accessed by patients when they need them most. At J&J, we are proud to have been part of the UK’s health innovation story for more than a century. We believe that turning ambition into delivery requires a clearer focus on the foundations that enable innovation to reach patients. We have had a substantial and long-term economic presence, with our expertise serving as the grounds for successful partnerships with patients, healthcare providers, clinical researchers and the NHS. Recent national developments are a step in the right direction The UK Government’s recent announcements on the life sciences industry are an important move to help address concerns around medicines access, innovation and the UK’s international standing. This includes a welcome planned increase to the baseline cost-effectiveness threshold (the first change to be made since its introduction in the early 2000s). While it is crucial to get this implemented properly, this seems like a step in the right direction — providing a starting point towards meaningful policy reform, industry partnership and progress for patients. The true impact of stifling medicine innovation in the UK compared with our peers These positive developments come at a critical time, but they do not fix everything. Over the past decade, spending on branded medicines has fallen in real terms, even as the NHS budget has grown by a third.[i] Years of cost-containment have left the UK health system ill-prepared for the health challenges of today, with short-term savings creating long-term consequences. Right now, access to innovative medicines in the UK lags behind almost every major European country[ii]; the UK ranks 16th and 18th among 19 comparable countries for preventable and treatable causes of mortality.[iii]These are conditions for which effective medicines already exist. Even when new medicines are approved, access is often restricted. One year after launch, usage of innovative treatments in England is just over half the average of comparator countries such as France, Germany and Spain.[iv] The effect is that people living with cancer, autoimmune conditions and rare diseases wait longer to access therapies that are already transforming lives elsewhere in Europe. And even at its new level, the UK’s Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) clawback rate remains higher than in comparable countries.[v] J&J is committed to working together to develop a new pricing and access framework that is stable, predictable and internationally competitive — enabling the UK to regain its position as a leading destination for life sciences. Seeing the value of health and medicines investment as a catalyst for prosperity and growth Timely access to the right treatment achieves two things; it keeps people healthy and prevents disease worsening so they can participate in society and a thriving economy. New research from the WifOR Institute, funded by J&J, shows that countries that allocate more resources to health — especially when combined with a skilled workforce and strong infrastructure — consistently achieve better outcomes.[vi] > Timely access to the right treatment achieves two things; it keeps people > healthy and prevents disease worsening so they can participate in society and > a thriving economy. The UK Government’s recent recognition of the need for long-term change, setting out plans to increase investment in new medicines from 0.3 percent of GDP to 0.6 percent over the next 10 years is positive. It signals a move towards seeing health as one of our smartest long-term investments, underpinning the UK’s international competitiveness by beginning to bring us nearer to the levels in other major European countries. This mindset shift is critical to getting medicines to patients, and the life sciences ecosystem, including the pharmaceutical sector as a cornerstone, plays a pivotal role. It operates as a virtuous cycle — driven by the generation, production, investment in, access to and uptake of innovation. Exciting scientific developments and evolving treatment pathways mean that we have an opportunity to review the structures around medicines reimbursement to ensure they remain sustainable, competitive and responsive. At J&J, we have the knowledge and heritage to work hand-in-hand with the Government and all partners to achieve this. Together, we can realise the potential of medicine innovation in the UK Patients have the right to expect that science and innovation will reach them when they need it. Innovative treatments can be transformative for patients, meaning an improved quality of life or more precious time with loved ones. We fully support the Government’s ambitions for life sciences and the health of the nation. Now is the moment to deliver meaningful change — the NHS, Government and all system partners, including J&J, must look at what valuing innovation actually means when it comes to modernising the frameworks and mechanisms that support access and uptake. Practical ways to do this include: * Establishing a new pricing and access framework that is stable, predictable and internationally competitive. * Evolving medicines appraisal methods and processes, to deliver on the commitments of the UK-US Economic Prosperity Deal. * Adapting thresholds and value frameworks to ensure they are fit for the future — in the context of wider system pressures, including inflation, and the evolution of medical innovation requiring new approaches to assessment and access. > the NHS, Government and all system partners, including J&J, must look at what > valuing innovation actually means when it comes to modernising the frameworks > and mechanisms that support access and uptake. By truly recognising the value of health as an investment, rather than as a cost, we can return the UK to a more competitive position. The direction of travel is positive. At J&J, we stand ready to work in partnership to help ensure the UK is once again the best place in the world to research, develop and access medicines. Follow Johnson & Johnson Innovative Medicine UK on LinkedIn for updates on our business, our people and our community. CP-562703 | January 2026 -------------------------------------------------------------------------------- [i] House of Commons Library (2026). ‘NHS Funding and Expenditure’ Research Briefing. Available at: https://commonslibrary.parliament.uk/research-briefings/sn00724/ (Accessed January 2026). [ii] IQVIA & EFPIA (2025). EFPIA Patients W.A.I.T Indicator 2024 Survey. Available at: https://efpia.eu/media/oeganukm/efpia-patients-wait-indicator-2024-final-110425.pdf. (Accessed January 2026) [iii] The Kings Fund (2022). ‘How does the NHS compare to the health care systems of other countries?’ Available at: https://www.kingsfund.org.uk/insight-and-analysis/reports/nhs-compare-health-care-systems-other-countries (Accessed January 2026) [iv] Office for Life Sciences (2024). Life sciences competitiveness indicators 2024: summary. Available at: https://www.gov.uk/government/publications/life-sciences-sector-data-2024/life-sciences-competitiveness-indicators-2024-summary (Accessed January 2026). [v] ABPI. VPAG payment rate for newer medicines will be 14.5% in 2026. December 2025. Available at: https://www.abpi.org.uk/media/news/2025/december/vpag-payment-rate-for-newer-medicines-will-be-145-in-2026/. (Accessed January 2026). [vi] WifOR Institute (2025). Healthy Returns: A Catalyst for Economic Growth and Resilience. Available at: https://www.wifor.com/en/download/healthy-returns-a-catalyst-for-economic-growth-and-resilience/?wpdmdl=360794&refresh=6942abe7a7f511765977063. (Accessed January 2026).

The U.K. and China have announced a new services partnership to support British businesses operating in China, including through visa-free travel for short stays. The partnership will see Beijing relax its visa rules for British citizens, adding the U.K. to its visa-free list of countries. This will enable visits of up to 30 days for business and tourism without the need for a visa. The timings of the visa change have not yet been set out. The partnership focuses on better collaboration for businesses in healthcare, financial and professional services, legal services, education and skills — areas where British firms often face regulatory or administrative hurdles.  Britain and China have also agreed to conduct a “feasibility study” to explore whether to enter negotiations towards a bilateral services agreement. If it proceeds, this would establish clear and legally binding rules for U.K. firms doing business in China. Prime Minister Keir Starmer said: “As one of the world’s economic powerhouses, businesses have been crying out for ways to grow their footprints in China. “We’ll make it easier for them to do so – including via relaxed visa rules for short-term travel — supporting them to expand abroad, all while boosting growth and jobs at home.” The U.K. and China have also signed pacts covering co-operation on conformity assessments for exports from the U.K. to China, food safety, animal, and plant quarantine health and the work the UK-China Joint Economic and Trade Commission. The two sides aren’t planning to publish the full texts of the pacts.

BEIJING, China — British Prime Minister Keir Starmer on Wednesday rejected U.S. criticism of his government’s deal to hand over sovereignty of the Chagos Islands — pointing out that key members of Donald Trump’s administration openly backed it just months ago. Speaking to reporters on a trip to China, Starmer said renewed talks on the agreement — which sees Britain cede sovereignty of the islands housing U.S. military base Diego Garcia to Mauritius — were now underway with Washington D.C. But the British PM highlighted “very clear” previous statements of support for the deal by U.S. Secretary of State Marco Rubio and Secretary of Defense Pete Hegseth. “It has been raised with the White House at the tail end of last week, over the weekend and into the early part of this week,” Starmer said of ongoing engagement on the issue. “The position, as you know, is that when the Trump administration came in, we paused for three months to give them time to consider the Chagos deal, which they did at agency level. “And once they’d done that, they were very clear in the pronouncements about the fact that they supported the deal, and they were announcements made by… the defense secretary … I think Marco Rubio as well, and by President Trump himself.” Under the arrangement, struck last year after months of negotiations, the Diego Garcia military base will remain under U.K. and U.S. control for the next 99 years. The Mauritian government has long claimed it was forced to give up the islands for its own independence from Britain in 1968, and it will receive payments from the U.K. for the new set-up. Hegseth publicly backed the agreement in a statement issued last May, saying in a social media post that the “very important” agreement “secures the operational capabilities of the base and key US national security interests in the region. We are confident the base is protected for many years ahead.” Rubio — who had been more hawkish on the deal before taking a job in the Trump administration — issued a statement in May hailing the “United Kingdom and Mauritius for their leadership, vision, and commitment to ensure that Diego Garcia remains fully operational for the duration of this agreement.” But Trump blindsided London last week with a Truth Social post calling the deal an act of “great stupidity” without any justification. Opposition politicians, including Reform UK Leader and Trump ally Nigel Farage, welcomed the change of stance, with Farage saying: “The Americans have woken up to the fact that they were lied to.”

ABOARD THE PRIME MINISTER’S PLANE TO BEIJING — Keir Starmer rejected his Canadian counterpart’s call for mid-sized countries to band together in the face of unpredictable global powers — and insisted his “common sense” British approach will do just fine. The British prime minister arrives in China Wednesday for a trip aimed at rebooting the U.K.’s relationship with the Asian superpower. He’s the latest Western leader to make the visit — which will include a meeting with Chinese President Xi Jinping — after trips by Carney and France’s Emmanuel Macron. Carney used a searing speech at the World Economic Forum last week to warn of the “rupture” caused by “great powers” acting in their own self-interest. While he did not namecheck Donald Trump’s administration, the speech riled the U.S. president, who insisted: “Canada lives because of the United States.” The Canadian PM had called for middle powers to work together to “build something bigger, better, stronger, more just.” Starmer was pressed on those remarks on board his flight to China Tuesday. Asked whether he agreed that the old global order is dead — and whether smaller powers need to team up to push back at the U.S. and China, Starmer defended his own policy of trying to build bridges with Trump, Xi and the European Union all at once. “I’m a pragmatist, a British pragmatist applying common sense, and therefore I’m pleased that we have a good relationship with the U.S. on defense, security, intelligence and on trade and prosperity,” he says. “It’s very important that we maintain that good relationship.” He added: “Equally, we are moving forward with a better relationship with the EU. We had a very good summit last year with 10 strands of agreement. “We’ll have another summit this year with the EU, which I hope will be iterative, as well as following through on what we’ve already agreed. “And I’ve consistently said I’m not choosing between the U.S. and Europe. I’m really glad that the UK has got good relations with both.” Starmer’s government — which faces pressure from opposition parties back home as it re-engages with China — has stressed that it wants to cooperate, compete with and challenge Beijing when necessary, as it bids to build economic ties to aid the sputtering U.K. economy. “Obviously, China is the second biggest economy in the world, one of our biggest trading partners,” the British PM — who is flying with an entourage of British CEOs and business reps — said Tuesday. “And under the last government, we veered from the golden age to the ice age. And what I want to do is follow through on the approach I’ve set out a number of times now … which is a comprehensive and consistent approach to China. “I do think there are opportunities, but obviously we will never compromise national security in taking those opportunities.”

LONDON — Keir Starmer is off to China to try to lock in some economic wins he can shout about back home. But some of the trickiest trade issues are already being placed firmly in the “too difficult” box. The U.K.’s trade ministry quietly dispatched several delegations to Beijing over the fall to hash out deals with the Chinese commerce ministry and lay the groundwork for the British prime minister’s visit, which gets going in earnest Wednesday. But the visit comes as Britain faces growing pressure from its Western allies to combat Chinese industrial overproduction — and just weeks after Starmer handed his trade chief new powers to move faster in imposing tariffs on cheap, subsidized imports from countries like China. For now, then, the aim is to secure progress in areas that are seen as less sensitive. Starmer’s delegation of CEOs and chairs will split their time between Beijing and Shanghai, with executives representing City giants and high-profile British brands including HSBC, Standard Chartered, Schroders, and the London Stock Exchange Group, alongside AstraZeneca, Jaguar Land Rover, Octopus Energy, and Brompton filling out the cast list. Starmer will be flanked on his visit by Trade Secretary Peter Kyle and City Minister Lucy Rigby. Despite the weighty delegation, ministers insist the approach is deliberately narrow. “We have a very clear-eyed approach when it comes to China,” Security Minister Dan Jarvis said Monday. “Where it is in our national interest to cooperate and work closely with [China], then we will do so. But when it’s our national security interest to safeguard against the threats that [they] pose, we will absolutely do that.” Starmer’s wishlist will be carefully calibrated not to rock the boat. Drumming up Chinese cash for heavy energy infrastructure, including sensitive wind turbine technology, is off the table. Instead, the U.K. has been pushing for lower whisky tariffs, improved market access for services firms, recognition of professional qualifications, banking and insurance licences for British companies operating in China, easier cross-border investment, and visa-free travel for short stays. With China fiercely protective of its domestic market, some of those asks will be easier said than done. Here’s POLITICO’s pro guide to where it could get bumpy. CHAMPIONING THE CITY OF LONDON Britain’s share of China’s services market was a modest 2.7 percent in 2024 — and U.K. firms are itching for more work in the country. British officials have been pushing for recognition of professional qualifications for accountants, designers and architects — which would allow professionals to practice in China without re-licensing locally — and visa-free travel for short stays. Vocational accreditation is a “long-standing issue” in the bilateral relationship, with “little movement” so far on persuading Beijing to recognize U.K. professional credentials as equivalent to its own, according to a senior industry representative familiar with the talks, who, like others in this report, was granted anonymity to speak freely. But while the U.K.’s allies in the European Union and the U.S. have imposed tariffs on Chinese EVs, the U.K. has resisted pressure to do so. | Jessica Lee/EPA Britain is one of the few developed countries still missing from China’s visa-free list, which now includes France, Germany, Italy, Spain, the Netherlands, Switzerland, Australia, New Zealand, Japan, Saudi Arabia, Russia and Sweden.  Starmer is hoping to mirror a deal struck by Canadian PM Mark Carney, whose own China visit unlocked visa-free travel for Canadians.  The hope is that easier business travel will reduce friction and make it easier for people to travel and explore opportunities on the ground — it would allow visa-free travel for British citizens, giving them the ability to travel for tourism, attend business conferences, visit friends and family, and participate in short exchange activities.  SMOOTHING FINANCIAL FLOWS The Financial Conduct Authority’s Chair Ashley Alder is also flying out to Beijing, hoping to secure closer alignment between the two countries’ capital markets. He’ll represent Britain’s financial watchdog at the inaugural U.K-China Financial Working Group in Beijing — and bang the drum for better market connectivity between the U.K. and China. Expect emphasis on the cross-border investments mechanism known as the Shanghai-London and Shenzhen-London Stock Connect, plus data sovereignty issues associated with Chinese companies jointly listing on the London Stock Exchange, two figures familiar with the planning said. The Stock Connect opened up both markets to investors in 2019 which, according to FCA Chair Ashley Alder, led to listings worth almost $6 billion. “Technical obstacles have so far prevented us from realizing Stock Connect’s full potential,” Alder said in a speech last year. Alder pointed to a memorandum of understanding being drawn up between the FCA and China’s National Financial Regulatory Administration, which he said is “critical” to allow information to be shared quickly and for firms to be supervised across borders. But that raises its own concerns about Chinese use of data. “The goods wins are easier,” said a senior British business representative briefed on the talks. “Some of the service ones are more difficult.” TAPPING INTO CHINA’S BIOTECH BOOM Pharma executives, including AstraZeneca’s CEO Pascal Soriot, are among those heading to China, as Britain tries to burnish its credentials as a global life sciences hub — and attract foreign direct investment. China, once known mainly for generics — cheaper versions of branded medicine that deliver the same treatment — has rapidly emerged as a pharma powerhouse. According to ING Bank’s global healthcare lead, Stephen Farrelly, the country has “effectively replaced Europe” as a center of innovation. ING data shows China’s share of global innovative drug approvals jumped from just 4 percent in 2014 to 27 percent in 2024. Pharma executives, including AstraZeneca’s CEO Pascal Soriot, are among those heading to China, as Britain tries to burnish its credentials as a global life sciences hub — and attract foreign direct investment. | John G. Mabanglo/EPA Several blockbuster drug patents are set to expire in the coming years, opening the door for cheaper generic competitors. To refill thinning pipelines, drugmakers are increasingly turning to biotech companies. British pharma giant GSK signed a licensing deal with Chinese biotech firm Hengrui Pharma last July. “Because of the increasing relevance of China, the big pharma industry and the U.K. by definition is now looking to China as a source of those new innovative therapies,” Farrelly said. There are already signs of progress. Science Minister Patrick Vallance said late last year that the U.K. and China are ready to work together in “uncontroversial” areas, including health, after talks with his Chinese counterpart. AstraZeneca, the University of Cambridge and Beijing municipal parties have already signed a partnership to share expertise. And earlier this year, the U.K. announced plans to become a “global first choice for clinical trials.” “The U.K. can really help China with the trust gap” when it comes to getting drugs onto the market, said Quin Wills, CEO of Ochre, a biotech company operating in New York, Oxford and Taiwan. “The U.K. could become a global gold stamp for China. We could be like a regulatory bridgehead where [healthcare regulator] MHRA, now separate from the EU since Brexit, can do its own thing and can maybe offer a 150-day streamlined clinical approval process for China as part of a broader agreement.” SLASHING WHISKY TARIFFS  The U.K. has also been pushing for lowered tariffs on whisky alongside wider agri-food market access, according to two of the industry figures familiar with the planning cited earlier. Talks at the end of 2024 between then-Trade Secretary Jonathan Reynolds and his Chinese counterpart ended Covid-era restrictions on exports, reopening pork market access. But in February 2025 China doubled its import tariffs on brandy and whisky, removing its provisional 5 percent tariff and applying the 10 percent most-favored-nation rate. “The whisky and brandy issue became China leverage,” said the senior British business representative briefed on the talks. “I think that they’re probably going to get rid of the tariff.”  It’s not yet clear how China would lower whisky tariffs without breaching World Trade Organization rules, which say it would have to lower its tariffs to all other countries too. INDUSTRIAL TENSIONS The trip comes as the U.K. faces growing international pressure to take a tougher line on Chinese industrial overproduction, particularly of steel and electric cars. But in February 2025 China doubled its import tariffs on brandy and whisky, removing its provisional 5 percent tariff and applying the 10 percent most-favored-nation rate. | Yonhap/EPA But while the U.K.’s allies in the European Union and the U.S. have imposed tariffs on Chinese EVs, the U.K. has resisted pressure to do so. There’s a deal “in the works” between Chinese EV maker and Jaguar Land Rover, said the senior British business representative briefed on the talks quoted higher, where the two are “looking for a big investment announcement. But nothing has been agreed.” The deal would see the Chinese EV maker use JLR’s factory in the U.K. to build cars in Britain, the FT reported last week. “Chinese companies are increasingly focused on localising their operations,” said another business representative familiar with the talks, noting Chinese EV makers are “realising that just flaunting their products overseas won’t be a sustainable long term model.” It’s unlikely Starmer will land a deal on heavy energy infrastructure, including wind turbine technology, that could leave Britain vulnerable to China. The U.K. has still not decided whether to let Ming Yang, a Chinese firm, invest £1.5 billion in a wind farm off the coast of Scotland.

January 2026 I GB-73006 Disclaimer  POLITICAL ADVERTISEMENT  * This is sponsored content from AstraZeneca.  * The advertisement is linked to public policy debates on the future of cardiovascular care in the UK.  * This content has been paid for and developed by AstraZeneca UK  Cardiovascular disease (CVD) has shaped the nation’s health for generations. It remains a leading cause of death and a major driver of long-term sickness, yet it is also one of the most preventable. Today, 8 million people in the U.K. live with CVD, and early deaths from CVD in England have reached a 14-year high.1,2 The reality is stark: without urgent action, one million more could live with CVD by 2030 — and two million by 2040.1  Tackling CVD is not only a moral imperative, it’s an economic necessity. In the U.K., 2.5 million working-age people are economically inactive due to long-term sickness, and CVD contributes to long-term sickness at unprecedented levels3 Each year, CVD costs the U.K. economy an estimated £24 billion, straining public finances, dampening productivity and widening inequalities.4  In July 2023, AstraZeneca convened the CVD-risk coalition — with charities, clinical organizations and patient groups — to shape a coordinated response to these trends.   Today, the coalition has published Getting to the heart of the matter: A national action plan for tackling cardiovascular disease5 — a blueprint for decisive action and a call for the government and the NHS to confront CVD head on. It has a clear message: the tools exist to tackle this challenge, but we need leadership, investment, and a focus on prevention and early intervention to unlock meaningful change.  > the tools exist to tackle this challenge, but we need leadership, investment, > and a focus on prevention and early intervention to unlock meaningful change. Diagnosis and prevention gaps we cannot afford   CVD often arises from detectable and treatable conditions: hypertension, high cholesterol, diabetes, chronic kidney disease. Yet millions remain undiagnosed. Six million people in the U.K. don’t know they have high blood pressure — a silent driver of heart attacks, strokes and kidney disease.6,7   This systemic diagnosis gap is not the result of a lack of evidence or clinical consensus; rather, the longstanding pressure on primary and community care, fragmentation across services, and declining investment in public health. Between 2015/16 and 2023/24, funding for key preventative services — including smoking cessation and adult obesity support — fell sharply in real terms.8  Additionally, secondary prevention remains patchy across England. Despite clear treatment guidance from NICE, less than half of patients with CVD meet recommended cholesterol levels. Almost 30 percent of hypertension patients are not meeting recommended blood pressure targets or don’t have a recent blood pressure measurement in their records.9   The consequences are clear: progress on CVD outcomes has stalled, premature deaths are rising and those in England’s most deprived areas are four times more likely to die prematurely from CVD than those in the least deprived.10  > progress on CVD outcomes has stalled, premature deaths are rising and those in > England’s most deprived areas are four times more likely to die prematurely > from CVD than those in the least deprived We must place prevention at the heart of our health system.  A vision for proactive, personalized cardiovascular care  Early CVD prevention and treatment save lives and money. It benefits patients, reduces NHS pressure and strengthens the UK’s economic resilience.   A 20 percent reduction in CVD incidence could save the NHS £1.1 billion annually within five years and place 60-70,000 more people into work.11 Recent CVDACTION modeling suggests that even modest near-term improvements in treatment could prevent approximately 61,000 events of heart attack, stroke, heart failure admission and end-stage kidney disease in three years.12   This is not theoretical. We know what integrated, proactive models can do.   Unlocking the power of data and digital tools  Platforms like CVDPREVENT and CVDACTION already demonstrate how data-driven insights from GP records can flag undiagnosed or undertreated patients — enabling clinicians to prioritize, optimize treatment and thus prevent avoidable heart attacks and strokes every year.13,14  Additionally, as the NHS App becomes a digital ‘front door’, there is an opportunity to deliver personalized risk information, lifestyle guidance and seamless access to services.  But digital transformation requires investment in workforce capability, interoperability between systems and national procurement frameworks that can scale at pace.  Tom Keith Roach A neighborhood approach to prevention  Joined-up neighborhood services — across community pharmacies, general practice, specialist teams and local authorities — could identify risk earlier, manage long-term conditions holistically and reduce avoidable admissions.   Community pharmacy hypertension screening has delivered over two million blood pressure checks in a single year, identifying thousands previously unaware of their risk.15    The LUCID program, developed as part of a joint working initiative between AstraZeneca and University Hospitals Leicester, has shown that integrated care across nephrology specialists and primary care can identify high-risk chronic kidney disease patients and optimize their treatment, reducing emergency admissions and long-term NHS costs.16    But to truly deliver change, resources must be rebalanced toward primary and community care. Cardiovascular prevention cannot be driven from hospitals alone. The neighborhood service must be properly resourced, with contracts and incentives aligned to prevention and outcomes, not activity.  A whole-system effort to transform lives and the economy  The forthcoming Modern Service Framework for CVD, promised within the Government’s 10 Year Health Plan, presents a critical opportunity. This framework must: * Embed prevention into every level of care  * Enable earlier diagnosis using digital and community-based tools  * Support optimal treatment through data and workforce innovation  * Define clear national priorities backed by accountability  CVD is a health challenge and a national prosperity challenge. We cannot afford rising sickness, worsening inequalities, and an NHS stretched by late-stage, preventable disease. The link between health and wealth has never been clearer: investing in CVD prevention will deliver both immediate and long-term returns.  > The link between health and wealth has never been clearer: investing in CVD > prevention will deliver both immediate and long-term returns. The action plan published today provides a clear, evidence-based roadmap.5 It calls for:  * National clinical and political leadership  * Ambitious targets, including a 20 percent reduction in incidence  * Investment in prevention and the expansion of Health Checks  * Improved uptake of effective treatments, guided by data  * Digital and diagnostic excellence across neighborhoods  * Partnership working at every level  A call to action  CVD has affected too many lives for too long. But progress is within reach. The decisions we make today will determine whether the next decade is defined by a widening crisis or a renewed national effort to prevent avoidable illness.  AstraZeneca stands ready to support the government, the NHS and partners to deliver the change our country needs. The time to act is now.  Find out more at astrazeneca.co.uk   References [1] British Heart Foundation. UK factsheet. January 2026. Available at: https://www.bhf.org.uk/-/media/files/for-professionals/research/heart-statistics/bhf-cvd-statistics-uk-factsheet-jan26.pdf.Last accessed: January 2026. [2] British Medical Journal. Early deaths from cardiovascular disease reach 14 year high in England. British Medical Journal. January 2024. Available at: https://www.bmj.com/content/384/bmj.q176. Last accessed: December 2025.   [3] Rising ill-health and economic inactivity because of long-term sickness, UK: 2019 to 2023. Office for National Statistics. Available at: https://www.ons.gov.uk/employmentandlabourmarket/peoplenotinwork/economicinactivity/articles/risingillhealthandeconomicinactivitybecauseoflongtermsicknessuk/2019to2023. Last accessed: December 2025.   [4] UK Government. UIN HL5942. March 2025. Available at: https://questions-statements.parliament.uk/written-questions/detail/2025-03-18/hl5942. Last accessed: December 2025. [5] Getting to the heart of the matter. A national action plan for tackling cardiovascular disease. AstraZeneca. 2025. Available at: https://qr.short.az/r/Getting-to-the-heart-of-the-matter. Last accessed: January 2026. [6] Blood Pressure UK. Why is know your numbers! needed?. Available at: https://www.bloodpressureuk.org/know-your-numbers/why-is-know-your-numbers-needed/. Last accessed: December 2025.   [7] Department of Health and Social Care. Get your blood pressure checked. March 2024. Available at: https://www.gov.uk/government/news/get-your-blood-pressure-checked. Last accessed: December 2025. [8] The Health Foundation. Investing in the public health grant. February 2025. Available at: https://www.health.org.uk/reports-and-analysis/analysis/investing-in-the-public-health-grant. Last Accessed January 2026.  [9] CVDPREVENT. CVDP Annual Audit Report 2025. March 2025. Available at: https://static1.squarespace.com/static/65eafc36395e4d64e18a3232/t/6937fb8666a6d23761182c05/1765276550824/CVDPREVENT+Fifth+Annual+Report.pdf Last Accessed: January 2026. [10] Public Health England. Health matters: preventing cardiovascular disease. February 2019. Available at: https://www.gov.uk/government/publications/health-matters-preventing-cardiovascular-disease/health-matters-preventing-cardiovascular-disease. Last accessed: December 2025. [11] Tony Blair Institute for Global Change. The economic case for Protect Britain, a preventative health care delivery programme. July 2024. Available at: https://assets.ctfassets.net/75ila1cntaeh/7CcuI38C3mxgps6lC9O2iA/825bf2a41f933cf719459087c1599190/Tony_Blair_Institute_for_Global_Change__The_Economic_Case_for_Protect_Britain__July_2024.pdf Last accessed January 2026 [12] Into-Action.Health. Powering the prevention shift – The CVDACTION impact model.  September 2025. Available at: https://www.into-action.health/_files/ugd/ee4262_81e75612f13e403aab6594727b338771.pdf. Last Accessed January 2026. [13]Data & Improvement Tool. CVDPREVENT. Available at: https://www.cvdprevent.nhs.uk/. Last accessed: December 2025.   [14] Transforming the prevention of CVD. CVDACTION. Health Innovation Network. Available at: https://thehealthinnovationnetwork.co.uk/case_studies/transforming-the-prevention-of-cvd/. Last accessed: December 2025. [15] NHS Business Services Authority. Dispensing contractors’ data. Available at: https://www.nhsbsa.nhs.uk/prescription-data/dispensing-data/dispensing-contractors-data . Last Accessed January 2026 [16] AstraZeneca UK. Executive summary of Joint Working outputs. Pan Leicester Integrated Chronic Kidney Disease (CKD) Transformation Project: a quality improvement project to identify CKD patients in primary care suitable for virtual management to improve patient outcomes. (LUCID). July 2024. Available at: https://www.astrazeneca.co.uk/content/dam/intelligentcontent/unbranded/astrazeneca/uk/en/pdf/work-with-nhs-uk/Executive_Summary_of_Joint_Working_Outputs_Pan_Leicester.pdf. Last Accessed: January 2026

LONDON — Kemi Badenoch’s Conservative Party retracted a contentious statement that referred to the mental health of former Tory cabinet minister Suella Braverman who earlier Monday announced her defection to Nigel Farage’s Reform UK. Braverman, a former home secretary, became the insurgent right-wing outfit’s eighth MP on Monday when she resigned her Tory membership of 30 years. Braverman will stay on as MP for her Fareham and Waterlooville constituency. Following her switch to Farage’s poll-topping party, the Conservatives sent a statement to journalists lambasting her record, and making reference to her mental health. “It was always a matter of when, not if, Suella would defect. The Conservatives did all we could to look after Suella’s mental health, but she was clearly very unhappy,” the spokesperson said. The backlash came quickly. A Reform spokesperson said: “It’s gutter politics, a sign of what the Conservative Party has become.” Government minister Mike Tapp described the remarks as “below the standards we expect,” while Labour colleague Josh Fenton-Glynn said it was “horrible.” “Attacking someone on mental health is wrong,” he wrote on X. “The kind of first draft of an email you do before having a cup of tea and letting your better angels take over.” A new version of the Conservative statement, which was sent around an hour-and-a-half after the original, pointedly omitted the “mental health” comments, with Conservative officials saying the original “draft” had been sent in “error.”  It is the latest in a series of Conservative attacks on defectors to Reform. When Robert Jenrick quit as shadow justice secretary to join Reform, Badenoch shrugged off the departure of one of her most recognizable MPs. She painted Jenrick as someone who had been working to undermine her party: “So I’m just glad that Nigel Farage is doing my spring cleaning for me. He’s taking away my problems.” When former Chancellor Nadhim Zahawi jumped to Farage’s ship, Conservative officials let it be known that he’d been asking Badenoch for a peerage just weeks before. Sam Francis contributed reporting.